본문 바로가기
  • Home

Stimulation of the Immune Response by Herbal Formulas for Taeeumin

  • Journal of Sasang Constitution and Immune Medicine
  • Abbr : JSCIM
  • 2010, 22(3), pp.141~151
  • Publisher : The Society of Sasang Constitution and Immune Medicine
  • Research Area : Medicine and Pharmacy > Korean Medicine

정다영 1 하혜경 2 이호영 1 이진아 1 Nam-Hun Lee 1 이준경 1 황대선 1 신현규 1

1한국한의학연구원 표준화연구본부 한약EBM연구센터
2한국한의학연구원 한약EBM연구센터

Accredited

ABSTRACT

1. Objectives Three herbal formulas (Yuldahanso-tang, Chungsimyonja-tang, and Taeeumjowi-tang) for Taeeumin were applied to investigate the immunological activities on antigen (Ag)-specific or Ag-non-specific immune responses in murine macrophage cell line (RAW 264.7) and ovalbumin (OVA)-immunized mice. 2. Methods This study was carried out in nitric oxide (NO) synthesis in RAW 264.7 cells and cellular proliferation in mouse splenocytes according to three herbal formulas. C57BL/6 mice were immunized intraperitonially with OVA/ aluminium (100 ㎍/200 ㎍/mouse) on day 1, 8, and 15. Three herbal formulas were administrated to mice orally for 3 weeks from day 1. On day 22, OVA-, lipopolysaccharide (LPS)-, and concanavalin A (Con A)-stimulated splenocyte proliferation and antibodies (OVA-specific antibodies of the IgG, IgG1, and total IgM classes) in plasma were measured. 3. Results Yuldahanso-tang and Chungsimyonja-tang increased NO synthesis in RAW 264.7 cells. Three herbal formulas significantly enhanced cellular proliferation by LPS and Con A in splenocytes from OVA-immunized mice (p<.001). Three herbal formulas for Taeeumin also significantly enhanced plasma OVA-specific IgG, IgG1, and total IgM levels compared with the OVA/Alum group. 4. Conclusion These results suggested that three herbal formulas for Taeeumin could be used as stimulator of immune response.

Journal Copyright Policy

BY-NC 아이콘

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Citation status

* References for papers published after 2025 are currently being built.